Breaking News, Trials & Filings

Baxter’s Gammagard Shows Promise in AD

Baxter International and New York-Presbyterian Hospital/Weill Cornell Medical Center achieved positive results from an 18-month Phase II study of Gammagard Liquid and Gammagard S/D in mild-to-moderate Alzheimer’s disease.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Baxter International and New York-Presbyterian Hospital/Weill Cornell Medical Center achieved positive results from an 18-month Phase II study of Gammagard Liquid and Gammagard S/D [Immune Globulin Intravenous (Human)] in mild-to-moderate Alzheimer’s disease. The study measured function and cognition using the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change rating (ADCS-CGIC) and the Alzheimer’s Disease Assessment Scale-Cognitive Subscale score (ADAS-Cog). After 18...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters